CTCs in Clinical Research
RareCyte enables practical deployment of circulating tumor cell (CTC) and rare cell-based liquid biopsy with instrumentation and consumables that provide an exquisitely sensitive, accurate, reproducible, and transparent workflow from blood collection to single cell isolation.
- Unbiased, reproducible, highly sensitive, and specific rare cell detection
- Scalable, high-capacity platform with workflow breakpoints, including slide banking, that enable multi-site execution
- Deploy through our global contract research organization (CRO) network or in your own lab
- Utilize cancer-specific panels or Developer panels for CTC biomarker analysis
- Custom assay and companion diagnostics co-development through our Precision Biology Services

WEBINAR: Analytical Validation of CTC Enumeration using the RareCyte Platform and Implementation in a Global Clinical Trial
Learn how the RareCyte platform for CTC analysis was validated in the Clinical Diagnostics Lab (CAP accredited CLIA Lab) at Eli Lilly and the platform added to a global clinical trial for further evaluation in collaboration with a CRO.
Speakers:
- Jeff Fill MBA, MT(ASCP)
Senior Director, Diagnostic and Experimental Pathology, Lilly Research Laboratories, Eli Lilly and Company - Arturo Ramirez PhD
Director of Oncology, RareCyte Inc.
Rare-cell applications for clinical research
RareCyte Liquid Biopsy technology is compatible with a broad range of sample types. This technology has been utilized across key research and clinical applications, from rare cell dentification to companion diagnostics development.
Applications
- Oncology
- Immuno-oncology
- Digital pathology
- Non-invasive prenatal testing (NIPT)
- Companion diagnostics
- Gene and cell therapy
RarePlex® Assays: Design and Analytical Validation |
Assay Design and Analytical Validation Presented by Dr. Tad George, SVP Biology R&D. RarePlex Assays are sensitive, specific, and reproducible assays for CTC detection and biomarker expression. Watch this video to gain insight into the principles RareCyte applies to its assay design and validation process. |
Biomarker detection and exploration
Up to two additional channels are available for target biomarker assessment using validated assay kits or using a kit that allows insertion of user-defined markers. RareCyte also provides precision biology services to develop custom biomarker assays for CTCs and a range of other cell types including immune cells, circulating fibroblasts and circulating fetal cells.
RarePlex® Panel and Developer Assays for CTC enumeration and characterization |
RarePlex Panel and Developer Assays for CTC Enumeration and Characterization. Presented by Arturo Ramirez, Ph.D., Director of Oncology R&D. This 7 minute overview of RarePlex Panel Kits and Developer technology highlights available circulating tumor cell assays from RareCyte. |
